Clovis spikes ovarian cancer combo after 'underwhelming' efficacy; Servier wins priority review for Tibsovo expansion

Clovis Oncology updated investors with its first quarter results on Wednesday morning, and among its revelations proved some troubling news for a Bristol Myers Squibb-partnered program.

Pairing its experimental lucitanib drug with Bristol Myers’ Opdivo in an ongoing Phase Ib/II study, Clovis reported that “underwhelming efficacy” has led them to cease development for the combo in non-clear-cell ovarian cancer, execs said in Wednesday morning’s earnings call.